AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen, Elevar Therapeutics - LARVOL DELTA

Rivoceranib in patients with pretreated metastatic thymic epithelial tumors: phase II multi-center KCSG LU23-09 (THRIVE) trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Solid Tumor • Thymic Epithelial Tumor • Thymus Cancer

Apatinib Plus PD-1 Blockade versus Chemotherapy After Prior Immunotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Cohort Study. (PubMed, Biologics) - "Apatinib plus PD-1 blockade was associated with longer survival and greater disease control than single-agent chemotherapy. Given the single-center retrospective design, limited sample size, treatment heterogeneity, incomplete biomarker characterization, and potential residual confounding, these findings are hypothesis-generating, do not establish causality, and require prospective validation."

IO biomarker • Journal • Retrospective data • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Anti-Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single-Arm Meta-Analysis. (PubMed, Cancer Med) - "The combination shows promising antitumor activity and a generally acceptable safety profile in R/M NPC, particularly for immunotherapy-naive patients. These findings support further investigation in well-designed randomized controlled trials, but confirmation of its role relative to standard therapies requires larger comparative studies."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Dermatology • Hypertension • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Safety and Efficacy of Apatinib Combined With Irinotecan Liposome Injection in the Treatment of Recurrent or Metastatic Osteosarcoma: A Single-Arm, Open-Label, Prospective Multicenter Clinical Study (ESMO 2026) - No abstract available

Clinical • Metastases • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Iparomlimab and Tuvonralimab (QL1706) Combined with Apatinib and Capecitabine for the Treatment of Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-Arm, Open-Label, Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Real-World Effectiveness of Camrelizumab Plus Rivoceranib in Unresectable Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Cannabigerol sensitizes hepatocellular carcinoma cells to rivoceranib through calcium-dependent suppression of PI3K-AKT-mTOR/E2F1 signaling (ESMO 2026) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor • E2F1

Transarterial chemoembolization (TACE) combined with Camrelizumab and Apatinib versus camrelizumab and apatinib in the treatment of unresectable hepatocellular carcinoma : A multicenter, open-label, randomized trial (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis (ESMO 2026) - No abstract available

Clinical • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Camrelizumab Plus Apatinib Combined with Gemcitabine and Oxaliplatin (GEMOX) as First-Line Treatment for Advanced Biliary Tract Cancer (BTC): A Biomarker Exploratory Phase II Trial (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Molecular determinants of durable response to Apatinib in pulmonary metastatic osteosarcoma (ESMO 2026) - No abstract available

Metastases • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Maintenance therapy with adebrelimab plus apatinib in extensive-stage small-cell lung cancer: a prospective, multicentre, single-arm phase II study (ESMO 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Irinotecan Liposome Plus Vincristine and Apatinib for Relapsed/Refractory Adult Rhabdomyosarcoma: An Exploratory Study (ESMO 2026) - No abstract available

Clinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

Retlirafusp alfa Combined with Rivoceranib, With or Without Zeprumetostat, in Patients with Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy (ESMO 2026) - No abstract available

Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor

Camrelizumab Plus Apatinib for Locally Advanced or Metastatic Malignant Ocular Adnexal Tumors: A Multicenter, Multi-cohort, Single-arm Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ocular Melanoma • Oncology

Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: a prospective phase II clinical study (EANO 2026) - P2 | "Camrelizumab in combination with apatinib neoadjuvant therapy showed excellent efficacy in recurrent high-grade gliomas, and was superior to PD1 inhibitor monotherapy neoadjuvant treatment in rGBM patients."

Clinical • Combination therapy • P2 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Gliosarcoma • High Grade Glioma • Oligodendroglioma • Oncology • Sarcoma • Solid Tumor • KDR

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, J Gastrointest Oncol) - "For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone...For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS...For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation."

Checkpoint inhibition • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Combination of vinorelbine capsules and the small molecule anti-angiogenic drug apatinib for first-line treatment of advanced triple-negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. (PubMed, Oncol Lett) - "Oral vinorelbine, whether used alone or in combination with other agents, has demonstrated efficacy in treating metastatic breast cancer...Due to the high cost of apatinib, the patient discontinued it and switched to a regimen of vinorelbine capsules combined with capecitabine...Notably, the combined treatment did not induce or worsen the patient's schizophrenia. Overall, the present case provided valuable insights in treating patients with breast cancer with schizophrenia."

Journal • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor • Triple Negative Breast Cancer

Antitumor Efficacy of Apatinib and Etoposide-Loaded D-α-Tocopheryl Polyethylene Glycol Succinate Mixed Micelles Against Multidrug-Resistant Ovarian Cancer Cells. (PubMed, Pharmaceutics) - "In the HeyA8-MDR xenograft model, APA/ETP-mTS suppressed tumor growth and resulted in the lowest final tumor weight without apparent overt toxicity based on body weight and survival observations. These results suggest that APA/ETP-mTS is a promising micellar co-delivery platform for hydrophobic anticancer drugs in MDR ovarian cancer."

Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer (clinicaltrials.gov) - P3 | N=184 | Active, not recruiting | Sponsor: Fudan University | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Preoperative Radiotherapy with Anlotinib or Apatinib and Disease-Free Survival for Locally Advanced Soft Tissue Sarcoma: Results of Prospective Phase II Clinical Trials (ASTRO 2026) - "Preoperative RT with or without TKI/PARPi enabled good survivals in most LA-STSs with similar MWC rates. Adding TKIs improved DFS, particularly in non-WDLS subtypes. Randomized trials are needed for confirmation."

Clinical • Metastases • P2 data • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Impact of early antibiotic exposure on efficacy of camrelizumab plus rivoceranib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC): a sub-analysis of CARES-310. (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Radiation-Associated Small Intestinal Angiosarcoma Presenting as Small Bowel Obstruction in a Gastric Cancer Survivor (ACG 2026) - "She received 6 cycles of neoadjuvant SOX (S-1 plus oxaliplatin) followed by total gastrectomy in October 2017 and subsequent adjuvant oral S-1. In November 2017 the disease progressed with enlargement of retroperitoneal nodes; she received 6 cycles of paclitaxel plus raltitrexed, then concurrent S-1 and volumetric modulated arc therapy (VMAT; 50 Gy in 25 fractions to the retroperitoneal region) in 2018, followed by oral apatinib until 2019...(C) MYC: nuclear positivity in approximately 20â30% of tumor cells, supporting a radiation-associated origin. (D) Ki-67: elevated proliferation index (approximately 30â40%), consistent with a high-grade, highly proliferative tumor."

Angiosarcoma • Cachexia • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Disorder • Oncology • Sarcoma • Solid Tumor • CD31 • MYC • PECAM1

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials. (PubMed, World J Gastrointest Pharmacol Ther) - "Our study compared the efficacy of the main first-line treatments recommended for unresectable HCC. While we were able to rank the magnitude of efficacy across these treatments, the intrinsic limitations of our methods (primarily the reconstruction of IPD and the indirect nature of the treatment comparisons) should be borne in mind."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor